Shares of Natera, Inc. (NASDAQ:NTRA) have received an average rating of “Buy” from the six analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $17.50.

A number of equities research analysts have issued reports on the company. Zacks Investment Research downgraded Natera from a “buy” rating to a “hold” rating in a research report on Thursday, May 11th. Canaccord Genuity boosted their price target on Natera from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Wednesday, May 10th. Finally, Cowen and Company lowered their price target on Natera from $17.00 to $14.00 and set an “outperform” rating for the company in a research report on Tuesday, March 14th.

Natera (NASDAQ:NTRA) traded up 3.2641% during trading on Monday, reaching $10.7911. The company had a trading volume of 83,296 shares. The company’s market capitalization is $570.65 million. The firm’s 50 day moving average is $10.15 and its 200-day moving average is $9.90. Natera has a 12 month low of $7.35 and a 12 month high of $13.74.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, May 9th. The medical research company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.09. Natera had a negative net margin of 60.89% and a negative return on equity of 101.63%. The firm had revenue of $46.90 million for the quarter, compared to analysts’ expectations of $42.82 million. During the same period last year, the firm posted ($0.17) EPS. Natera’s revenue was down 24.2% on a year-over-year basis. On average, equities analysts expect that Natera will post ($1.96) earnings per share for the current year.

Several large investors have recently modified their holdings of the company. Jennison Associates LLC increased its stake in shares of Natera by 133.3% in the first quarter. Jennison Associates LLC now owns 2,332,873 shares of the medical research company’s stock valued at $20,693,000 after buying an additional 1,333,050 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Natera by 4.4% in the first quarter. Vanguard Group Inc. now owns 2,007,708 shares of the medical research company’s stock valued at $17,808,000 after buying an additional 84,144 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Natera by 28.2% in the first quarter. Renaissance Technologies LLC now owns 411,400 shares of the medical research company’s stock valued at $3,649,000 after buying an additional 90,600 shares during the last quarter. State Street Corp increased its stake in shares of Natera by 2.9% in the fourth quarter. State Street Corp now owns 389,498 shares of the medical research company’s stock valued at $4,561,000 after buying an additional 11,067 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS increased its stake in shares of Natera by 67.3% in the first quarter. Kornitzer Capital Management Inc. KS now owns 356,965 shares of the medical research company’s stock valued at $3,166,000 after buying an additional 143,585 shares during the last quarter. 59.93% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Natera, Inc. (NTRA) Receives Average Rating of “Buy” from Brokerages” was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/06/19/natera-inc-ntra-receives-average-rating-of-buy-from-brokerages.html.

About Natera

Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.